DifGen

Miramar, USA
DifGen is engaged in developing and manufacturing pharmaceutical solutions.
Request Access
Report Incorrect Data
Page last updated

About DifGen

DifGen is a Healthcare company based in Miramar, USA. DifGen is engaged in developing and manufacturing pharmaceutical solutions. It operates on a Direct-to-Consumer (D2C) and B2B2C model. DifGen has completed 2 acquisitions, including Aveva and KriGen Pharmaceuticals. Its Indian entity Difgen Pharmaceuticals Private Limited reported revenue of ₹76.63 Cr. DifGen offers products and services including Generic Pharmaceuticals, Branded Generics, and Transdermal Systems. Its focus areas include Pharmaceuticals and Generic Drugs.

Company details

DifGen Pharmaceuticals is involved in the development, manufacturing, and supply of high-quality generic and branded generic products. The company operates across various dosage forms, focusing on complex generics and advanced transdermal systems through its subsidiary, Aveva Drug Delivery Systems Inc. Expertise is maintained in research and development, regulatory compliance, and supply chain management to ensure access to essential medicines. Solutions are provided for healthcare sectors, emphasizing affordability and innovation to improve patient outcomes globally.

Operational Areas
Healthcare → Pharmaceuticals & Distribution
Key Metrics
  • Indian entity revenue
    ₹76.63 Cr

    FY 2025 · +84% YoY

  • Indian entity net profit
    ₹7.52 Cr

    FY 2025 · 10% margin

  • Indian entity EBITDA
    ₹12.74 Cr

    FY 2025 · 17% margin

  • Investments & Acquisitions
    Aveva

    & 1 more

Products & Services of DifGen

DifGen offers a comprehensive portfolio of products and services, including Generic Pharmaceuticals, Branded Generics, and Transdermal Systems.

Generic Pharmaceuticals
Healthcare

Generic drugs are produced for affordable healthcare solutions.

Branded Generics
Healthcare

Branded generics are offered for accessible medical treatments.

Transdermal Systems
Healthcare

Advanced transdermal patches are manufactured for drug delivery.

Board of directors of Difgen Pharmaceuticals Private Limited (DifGen)

Difgen Pharmaceuticals Private Limited is the primary company behind DifGen. The board of Difgen Pharmaceuticals Private Limited currently have 11 directors; the longest-serving is Srinivasan Vedantham, appointed in 2022. 9 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Srinivasan Vedantham
DIN 09534573
Director06 May 20224 yrs 5 moDifgen Pharmaceuticals Private Limited
Zubin Keki Gandhi
DIN 00664632
Director24 May 20224 yrs 5 moDifgen Pharmaceuticals Private Limited
Yatin Kirtanlal Desai
DIN 00030719
Director24 May 20224 yrs 5 moDifgen Pharmaceuticals Private Limited
Punit Chunilal Thakrar
DIN 00351619
Director04 Jul 20224 yrs 3 moDifgen Pharmaceuticals Private Limited
Amol Ashok Walke
DIN 00664315
Director04 Jul 20224 yrs 3 moDifgen Pharmaceuticals Private Limited
Vijay Kumar Vasireddy
DIN 03262782
Director04 Nov 20223 yrs 11 moDifgen Pharmaceuticals Private Limited
Santhanakrishnan Srinivasan
DIN 09789679
Director15 Nov 20223 yrs 11 moDifgen Pharmaceuticals Private Limited
Ramandeep Singh Jaj
DIN 09789813
Director15 Nov 20223 yrs 11 moDifgen Pharmaceuticals Private Limited
Krishna Chandrasekaran
DIN 10243796
Director24 Jul 20233 yrs 3 moDifgen Pharmaceuticals Private Limited
Valiveti Brahmaji
DIN 00079255
Additional Director21 Jan 20251 yr 9 moDifgen Pharmaceuticals Private Limited
Narasimhan Sridhar Nagaarjun
DIN 10941810
Additional Director13 Feb 20251 yr 8 moDifgen Pharmaceuticals Private Limited

People of DifGen

18 people are tracked at DifGen (13 in leadership, 5 in team).

NameRoleGroup
Rakesh Kumar Shekhar
Sr. Director, Engineering & MaintenanceLeadership
Santhanakrishnan Srinivasan
Founder & Co-CEOLeadership
Ramandeep Singh Jaj
Founder & Co-CEOLeadership
Sukhad Juneja
Chief Scientific and Commercial OfficerLeadership
Yoel Diaz
Director, Quality and ComplianceLeadership
Radu Oancea
Vice President, Global EngineeringLeadership
Priya Gopalkrishnan
Sr. Director, Head Global Program & Alliance ManagementLeadership
Krishna Nawal
Director, Business Development, Portfolio, & IPLeadership
Madhuri Gupta
Sr. Director, Head Global Regulatory AffairsLeadership
Dipak Kulkarni
Sr. Director, Analytical R&DLeadership
Ravi Atmakuru
Sr. Director, Packaging Development, R&D and Technical ServicesLeadership
Christopher Adams
Vice President, Global Regulatory and R&D/Technical Services (US)Leadership
Nithun Saha
Vice President, R&DLeadership
Roland Lobo
Commissioning And Qualification EngineerTeam
Roberta Loomar
Global General CounselTeam
Sunilkumar Garre
Global Supplier Quality ManagerTeam
R.Ramasubramaniam
Lead - QA & QMSTeam
Sreelakshmi Nair
Research Associate -Quality AssuranceTeam
Premium access

Complete people profiles for DifGen

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of DifGen

Figures of Difgen Pharmaceuticals Private Limited, the primary company behind DifGen, for FY 2025. Revenue was ₹76.63 Cr (+84% year on year). Net profit was ₹7.52 Cr (10% margin). EBITDA was ₹12.74 Cr (17% margin).

  • ₹76.63 CrRevenue · FY 2025 · +84% YoY
  • ₹7.52 CrNet profit · 10% margin
  • ₹12.74 CrEBITDA · 17% margin
  • ₹1.00 CrPaid-up capital
  • 92Employees (provident fund records)

Balance sheet, profit and loss, cash flow and ratios of Difgen Pharmaceuticals Private Limited are on its company page.

Premium access

Detailed financial statements for DifGen

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by DifGen

DifGen has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Aveva and KriGen Pharmaceuticals.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
KriGen Pharmaceuticals
Injectable pharmaceuticals are manufactured by KriGen Pharmaceuticals as a CDMO.
krigenpharmaceuticals.comLillington, United States2018Dec 2023••••
Aveva
Drugs for multiple therapeutic areas are manufactured by Aveva.
avevadds.comMiramar, United States2003Apr 2023••••
Premium access

Complete acquisition details for DifGen

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of DifGen

2 dated milestones of DifGen, from founding to its latest funding, stage changes and deals.

  1. Acquisition Acquires Aveva.
  2. Acquisition Acquires KriGen Pharmaceuticals.

Top companies in Pharmaceuticals & Distribution

3 companies that operate in the same segment as DifGen (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Roivant Sciences
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
2014New York, New York, United StatesUSD 1.3 BUSD 8.26 M750
Amgen
Developer of pharmaceutical products for treating multiple diseases
1980Thousand Oaks, California, United StatesUSD 33.23 B28,000
AbbVie
Biopharmaceutical research and drug development are conducted globally by AbbVie.
2012Chicago, Illinois, United StatesUSD 61.16 B55,000
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about DifGen

The primary company behind DifGen, Difgen Pharmaceuticals Private Limited, reported revenue of ₹76.63 Cr for FY 2025, up 84% year on year.

DifGen Pharmaceuticals is involved in the development, manufacturing, and supply of high-quality generic and branded generic products. The company operates across various dosage forms, focusing on complex generics and advanced transdermal systems through its subsidiary, Aveva Drug Delivery Systems Inc. Expertise is maintained in research and development, regulatory compliance, and supply chain management to ensure access to essential medicines. Solutions are provided for healthcare sectors, emphasizing affordability and innovation to improve patient outcomes globally.

DifGen offers Generic Pharmaceuticals, Branded Generics, and Transdermal Systems.

DifGen has made 2 acquisitions, including Aveva, and KriGen Pharmaceuticals.

DifGen operates through Difgen Pharmaceuticals Private Limited.

The legal entities of DifGen currently have 11 directors, including Valiveti Brahmaji, Krishna Chandrasekaran, Zubin Keki Gandhi and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available